Lv3
320 积分 2025-05-10 加入
Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia
1个月前
已完结
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat
1个月前
已完结
Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress
2个月前
已完结
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study
6个月前
已完结
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
6个月前
已完结
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
6个月前
已完结
Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world
6个月前
已完结
A real-world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia
6个月前
已完结
Second malignancies in hydroxyurea and interferon‐treated Philadelphia‐negative myeloproliferative neoplasms
8个月前
已完结
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
9个月前
已完结
皖公网安备34019202002308
